Tag Archives: rituximab
New rituximab trial results from Norway
Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading
Unexpected findings & promoting monocausal claims, a cautionary tale
Article abstract: Stories of serendipitous discoveries in medicine incorrectly imply that the path from an unexpected observation to major discovery is straightforward or guaranteed. In this paper, I examine a case from the field of research about chronic fatigue syndrome (CFS). In Norway, … Continue reading
People with ME/CFS have long been told it’s all in their head – these scientists disagree
The Canary blog, 8 June 2016, by Conrad Bower: CFS have long been told it’s all in their head – these scientists disagree A conference bringing together the brightest minds in Myalgic Encephalomyelitis a.k.a Chronic Fatigue Syndrome (ME/CFS) research, presented … Continue reading
ME and rituximab in Notodden Norway
ME-foreldrene blog: Lecture by Hanne Thürmer, Notodden. RituxME and current development, 13 April 2016 Lecture by dr Hanne Thürmer, Notodden Hospital Original in Norwegian/Norsk original From a lecture given at the local department of the Norwegian ME-association in Notodden, avd … Continue reading
Video interview with parent Mary Dimmock about her son and rituximab
Episode 78 of Llewellyn King’s ME/CFS Alert videos interviews Mary Dimmock, whose son has ME and who is receiving RITUXAN (rituximab) treatment privately. (24 mins)
B-cell function in patients with ME/CFS
Research summary: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a heterogeneous condition of unknown etiology characterized by multiple symptoms including fatigue, post-exertional malaise and cognitive impairment, lasting for at least 6 months. Recently, two clinical trials of B-cell depletion therapy with rituximab (anti-CD20) reported convincing … Continue reading
To future GPs – psychosomatic should not be the default suspicion re ME/CFS
Time to swot up on chronic fatigue – Future general practitioners need to be made aware that “psychosomatic” should not be the default suspicion, by Michael Brooks in the New Statesman, Nov 12 2015 Around 250,000 people in the UK suffer from … Continue reading
Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab
Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading
UK rituximab trial fundraising total almost reached
Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading
Elevated autoantibodies found in CFS subgroup
Research highlights: β adrenergic and muscarinic acetylcholine receptor autoantibodies are elevated in a subset of patients with Chronic Fatigue Syndrome (CFS). Elevated autoantibodies in CFS correlate with elevated IgG1-3 subclass levels, thyreoperoxidase and ANA antibodies and T cell activation. In … Continue reading
